Zydus Lifesciences Limited announced that it has received an Establishment Inspection Report (EIR) from the USFDA for its transdermal patch manufacturing facility located at Pharmez, Ahmedabad. The inspection, which took place from July 15 to 19, 2024, resulted in a classification of Voluntary Action Indicated (VAI).
This classification indicates that the facility meets the necessary regulatory requirements, and no further action is required from the company regarding the inspection. The EIR signifies Zydus’s continued compliance with USFDA standards, further strengthening its capabilities in transdermal product manufacturing.
The company filed this update in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Ahmedabad Plane Crash